CJC-1295 with DAC: A Research Overview of the Long-Acting GHRH Analog

CJC-1295 comes in two forms that share a core peptide but behave very differently, and the difference is the whole point of this article. The version with DAC — a Drug Affinity Complex — binds to albumin in the blood and stays active for days, producing continuous stimulation of growth hormone release. That long action is what makes it interesting as a research tool, and also what makes its safety considerations distinct from, and in some respects more pointed than, the short-acting no-DAC version. Getting that distinction right is essential to discussing it honestly.

This overview summarizes what the published literature reports about CJC-1295 with DAC — its structure, mechanism, clinical record, and regulatory and safety status. It describes findings as they appeared in their study populations. It is not dosing guidance, medical advice, or a recommendation for use.

What CJC-1295 with DAC Is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), based on a modified GRF(1-29) sequence with substitutions that resist enzymatic breakdown. It was developed by ConjuChem Biotechnologies. The defining feature of the DAC version (also written as DAC: GRF) is the Drug Affinity Complex — a chemical group that enables the peptide to bind covalently to serum albumin after injection, dramatically extending its circulation time (CJC-1295 mechanism and history, reference entry).

The practical consequence is half-life. Native GHRH lasts minutes; the no-DAC form lasts roughly half an hour; CJC-1295 with DAC has an estimated half-life of about 5.8–8.1 days in humans (Teichman et al., J Clin Endocrinol Metab 2006). That is the line that separates the two versions: the no-DAC form mimics short, natural GH pulses, while the DAC form produces sustained, continuous GHRH receptor stimulation lasting more than a week per dose.

Mechanism of Action

Like all GHRH analogs, CJC-1295 binds the GHRH receptor on pituitary somatotroph cells and stimulates the synthesis and release of growth hormone, which in turn drives hepatic production of IGF-1 — the downstream mediator of most GH effects. What the DAC modification changes is not the receptor target but the signal duration.

A mechanistically important early finding is that this continuous stimulation did not abolish the body’s natural GH rhythm. A 2006 study reported that GH pulsatility was preserved during continuous CJC-1295 stimulation — trough, mean, and pulsatile GH secretion all rose without loss of the episodic release pattern (Alba et al. pulsatility findings, summarized). That detail matters because a complete loss of pulsatility would be expected to blunt the physiological response, so its preservation was treated as a meaningful result. The albumin-binding bioconjugation mechanism itself was established in rodent work by Jetté and colleagues in 2005.

The Clinical Record

CJC-1295 with DAC has more human pharmacology behind it than many research peptides, centered on a dose-escalation study by Teichman and colleagues in 2006 in healthy adults. After single subcutaneous doses, the study reported dose-dependent increases in mean plasma GH of roughly 2- to 10-fold, sustained for 6 or more days, and IGF-1 increases of about 1.5- to 3-fold, persisting for 9–11 days; after multiple doses, IGF-1 remained above baseline for up to 28 days. The compound was described as safe and relatively well tolerated, particularly at the lower doses, with no serious adverse reactions reported in that study (Teichman et al., J Clin Endocrinol Metab 2006).

Two limits frame that record honestly. The trials were small, early-phase, and conducted by the developer, and development did not continue to large confirmatory studies. There is real human pharmacology here — more than with most compounds in this space — but not the kind of large, controlled, long-term safety and efficacy program that underlies an approved drug.

Safety — Including the Trial Death, Stated Plainly

CJC-1295’s development was halted, and the reason should be reported precisely rather than sensationalized or omitted. A Phase 2 program in HIV-associated lipodystrophy was discontinued after the death of one trial participant. According to the account, the attending physician concluded that the most likely cause was asymptomatic coronary artery disease with plaque rupture and occlusion, and judged the event unrelated to CJC-1295; the program was nonetheless terminated as a precaution (trial discontinuation and physician attribution, reference entry). The honest reading is neither “CJC-1295 killed someone” nor a dismissal: a death occurred during the trial, it was attributed by the attending physician to pre-existing cardiovascular disease, and development stopped regardless.

Beyond that event, the DAC version carries a safety consideration intrinsic to its design. Because its half-life is in days rather than minutes, any adverse effect cannot be quickly reversed by stopping the compound, and its downstream elevation of GH/IGF-1 persists. Sustained elevation of the GH/IGF-1 axis also carries the general theoretical caution that applies to chronically high IGF-1, including concerns about abnormal cell growth. These are reasons the long-acting form warrants more caution than its short-acting counterpart, not less.

Regulatory and Anti-Doping Status

The status below reflects mid-2026 and is in flux; verify against current FDA notices before relying on it. CJC-1295 (in any form, including DAC) is not FDA-approved for any indication and is not a component of an approved drug; it has no active approval pathway. Its compounding status has been unsettled — placed among substances restricted from 503A compounding pending safety review, with the broader peptide-compounding picture changing during 2026 (compounding-status overview). A reclassification that permits compounding, if it occurs, would still not equal FDA drug approval.

The anti-doping status is unambiguous: the World Anti-Doping Agency lists CJC-1295 on its Prohibited List (Category S2, peptide hormones and growth factors / releasing agents), banned for athletes (WADA classification overview). Research-grade material is sold for laboratory use only and is, by its labeling, not for human consumption.

Why CJC-1295 with DAC Draws Research Interest

The appeal is specific. The DAC modification turns a minutes-long signal into a multi-day one, creating a sustained GHRH-stimulation model that researchers can use to study how prolonged GH/IGF-1 elevation affects metabolism — a useful contrast to the pulsatile, no-DAC version. The accurate framing is a long-acting GHRH analog with genuine but early human pharmacology, a development history that ended after a trial death (attributed to pre-existing disease), design-intrinsic safety considerations from its long half-life, no FDA approval, and a clear anti-doping prohibition. It is a serious research subject, and one that warrants serious caution.

For deeper reading, the primary literature cited throughout this article is the best starting point. For the short-acting counterpart and the common combination, see related growth hormone secretagogue topics in our peptide research library, which gathers reference material on the broader class of compounds discussed here.